[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100214809":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":54,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":70,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Oslo University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational study",null,"Patients diagnosed with PSM undergoing CRS with HIPEC.",[13],"Other: Observational study.",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Observational study.","Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.\n\nHIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.",[9],[20],"Observational study. Laboratory biomarker analysis.",[22],{"name":23,"affiliation":5,"role":24},"Kjersti Flatmark, MD PhD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+47 22 93 40 00","Kjersti.Flatmark@rr-research.no",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Annette Torgunrud Kristensen, PhD","+47 22 78 19 45","atj@rr-research.no",[35],{"facility":36,"status":37,"city":38,"state":10,"zip":10,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Norwegian Radium Hospital","RECRUITING","Oslo","Norway","NO",{"type":42,"coordinates":43},"Point",[44,45],10.74609,59.91273,{"lat":45,"lon":44},[48,49,50],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},{"name":23,"role":24,"phone":10,"phoneExt":10,"email":10},{"type":24,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Kjersti Flatmark","Professor",[55],{"name":56,"class":6},"The Research Council of Norway","100214809","peritoneal-surface-malignancies---characterization-models-and-treatment-strategies-100214809",false,"NCT02073500","Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies","Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.","PSM","Inclusion Criteria:\n\n* age \\> 18 years\n* confirmed diagnosis of peritoneal surface malignancy\n* candidate for CRS-HIPEC\n* written informed consent\n\nExclusion Criteria:\n\n* none\n\nApproximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.","ALL","18 Years",{"count":68,"type":69},300,"ESTIMATED","5 Years","OBSERVATIONAL","The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).",[74,75,76,77],"Pseudomyxoma Peritonei","Colorectal Carcinoma","Ovarian Carcinoma","Mesothelioma",[79,80,81,82,83,84,85,86],"Peritoneal carcinomatosis","Peritoneal surface malignancy","Cytoreductive surgery","Hyperthermic intraperitoneal chemotherapy","CRS","HIPEC","Prognostic biomarker","Predictive biomarker","2021-07-21",{"date":89,"type":90},"2021-07-28","ACTUAL",{"date":92,"type":90},"2009-09",{"date":94,"type":69},"2027-08",{"name":5,"class":6},1]